Cargando…

Fecal microbiota transplantation ameliorates active ulcerative colitis

Ulcerative colitis (UC) is a complex chronic pathological condition of the gut in which microbiota targeted treatment, such as fecal microbiota transplantation (FMT), has shown an encouraging effect. The aim of the present study was to investigate the efficacy and safety of FMT in patients with mild...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hui-Ting, Huang, Hong-Li, Xu, Hao-Ming, Luo, Qing-Ling, He, Jie, Li, Yong-Qiang, Zhou, You-Lian, Nie, Yu-Qiang, Zhou, Yong-Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086197/
https://www.ncbi.nlm.nih.gov/pubmed/32256746
http://dx.doi.org/10.3892/etm.2020.8512
_version_ 1783509077903540224
author Chen, Hui-Ting
Huang, Hong-Li
Xu, Hao-Ming
Luo, Qing-Ling
He, Jie
Li, Yong-Qiang
Zhou, You-Lian
Nie, Yu-Qiang
Zhou, Yong-Jian
author_facet Chen, Hui-Ting
Huang, Hong-Li
Xu, Hao-Ming
Luo, Qing-Ling
He, Jie
Li, Yong-Qiang
Zhou, You-Lian
Nie, Yu-Qiang
Zhou, Yong-Jian
author_sort Chen, Hui-Ting
collection PubMed
description Ulcerative colitis (UC) is a complex chronic pathological condition of the gut in which microbiota targeted treatment, such as fecal microbiota transplantation (FMT), has shown an encouraging effect. The aim of the present study was to investigate the efficacy and safety of FMT in patients with mild or moderate UC. A single-center, open-label study was designed, including 47 patients with mild or moderate active UC who received three treatments of fresh FMT via colonic transendoscopic enteral tubing within 1 week. The inflammatory bowel disease questionnaire, partial Mayo scores, colonoscopy, erythrocyte sedimentation rate, C-reactive protein level and procalcitoin values were used to assess the efficacy of FMT and alteration in gut microbiota was detected by 16S ribosomal RNA-sequencing. Before FMT, microbiota Faecalibacterium prausnitzii (F. prausnitzii) levels were significantly decreased in patients with UC compared with healthy donors (P<0.01). At 4 weeks post-FMT, F. prausnitzii levels were significantly increased (P<0.05), and the Mayo score was significantly decreased (1.91±1.07 at baseline vs. 4.02±1.47 at week 4; P<0.001) in patients with UC compared with healthy donors. Steroid-free clinical responses were reported in 37 patients (84.1%), and steroid-free clinical remission was achieved in 31 patients (70.5%) at week 4 post-FMT, however, steroid-free remission was not achieved in any patient. No adverse events were reported in 41 (93.2%) patients after FMT or during the 12-week follow-up. Shannon's diversity index and Chao1 estimator were also improved in patients with UC receiving FMT. In conclusion, the results of the present study suggested that FMT resulted in clinical remission in patients with mild to moderate UC, and that the remission may be associated with significant alterations to the intestinal microbiota of patients with UC. Furthermore, F. prausnitzii may serve as a diagnostic and therapeutic biomarker for the use of FMT in UC.
format Online
Article
Text
id pubmed-7086197
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-70861972020-04-02 Fecal microbiota transplantation ameliorates active ulcerative colitis Chen, Hui-Ting Huang, Hong-Li Xu, Hao-Ming Luo, Qing-Ling He, Jie Li, Yong-Qiang Zhou, You-Lian Nie, Yu-Qiang Zhou, Yong-Jian Exp Ther Med Articles Ulcerative colitis (UC) is a complex chronic pathological condition of the gut in which microbiota targeted treatment, such as fecal microbiota transplantation (FMT), has shown an encouraging effect. The aim of the present study was to investigate the efficacy and safety of FMT in patients with mild or moderate UC. A single-center, open-label study was designed, including 47 patients with mild or moderate active UC who received three treatments of fresh FMT via colonic transendoscopic enteral tubing within 1 week. The inflammatory bowel disease questionnaire, partial Mayo scores, colonoscopy, erythrocyte sedimentation rate, C-reactive protein level and procalcitoin values were used to assess the efficacy of FMT and alteration in gut microbiota was detected by 16S ribosomal RNA-sequencing. Before FMT, microbiota Faecalibacterium prausnitzii (F. prausnitzii) levels were significantly decreased in patients with UC compared with healthy donors (P<0.01). At 4 weeks post-FMT, F. prausnitzii levels were significantly increased (P<0.05), and the Mayo score was significantly decreased (1.91±1.07 at baseline vs. 4.02±1.47 at week 4; P<0.001) in patients with UC compared with healthy donors. Steroid-free clinical responses were reported in 37 patients (84.1%), and steroid-free clinical remission was achieved in 31 patients (70.5%) at week 4 post-FMT, however, steroid-free remission was not achieved in any patient. No adverse events were reported in 41 (93.2%) patients after FMT or during the 12-week follow-up. Shannon's diversity index and Chao1 estimator were also improved in patients with UC receiving FMT. In conclusion, the results of the present study suggested that FMT resulted in clinical remission in patients with mild to moderate UC, and that the remission may be associated with significant alterations to the intestinal microbiota of patients with UC. Furthermore, F. prausnitzii may serve as a diagnostic and therapeutic biomarker for the use of FMT in UC. D.A. Spandidos 2020-04 2020-02-11 /pmc/articles/PMC7086197/ /pubmed/32256746 http://dx.doi.org/10.3892/etm.2020.8512 Text en Copyright: © Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Chen, Hui-Ting
Huang, Hong-Li
Xu, Hao-Ming
Luo, Qing-Ling
He, Jie
Li, Yong-Qiang
Zhou, You-Lian
Nie, Yu-Qiang
Zhou, Yong-Jian
Fecal microbiota transplantation ameliorates active ulcerative colitis
title Fecal microbiota transplantation ameliorates active ulcerative colitis
title_full Fecal microbiota transplantation ameliorates active ulcerative colitis
title_fullStr Fecal microbiota transplantation ameliorates active ulcerative colitis
title_full_unstemmed Fecal microbiota transplantation ameliorates active ulcerative colitis
title_short Fecal microbiota transplantation ameliorates active ulcerative colitis
title_sort fecal microbiota transplantation ameliorates active ulcerative colitis
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086197/
https://www.ncbi.nlm.nih.gov/pubmed/32256746
http://dx.doi.org/10.3892/etm.2020.8512
work_keys_str_mv AT chenhuiting fecalmicrobiotatransplantationamelioratesactiveulcerativecolitis
AT huanghongli fecalmicrobiotatransplantationamelioratesactiveulcerativecolitis
AT xuhaoming fecalmicrobiotatransplantationamelioratesactiveulcerativecolitis
AT luoqingling fecalmicrobiotatransplantationamelioratesactiveulcerativecolitis
AT hejie fecalmicrobiotatransplantationamelioratesactiveulcerativecolitis
AT liyongqiang fecalmicrobiotatransplantationamelioratesactiveulcerativecolitis
AT zhouyoulian fecalmicrobiotatransplantationamelioratesactiveulcerativecolitis
AT nieyuqiang fecalmicrobiotatransplantationamelioratesactiveulcerativecolitis
AT zhouyongjian fecalmicrobiotatransplantationamelioratesactiveulcerativecolitis